Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Shinichi Yabuuchi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5002478976. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper

Papers 8

  1. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  2. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-1973↗
  3. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. First author DOI 10.1158/1078-0432.ccr-17-1115↗
  4. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. First author DOI 10.1038/bjc.2016.215↗
  5. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗
  6. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  7. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.054↗
  8. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Co-author DOI 10.1158/1535-7163.mct-12-0017↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. N.V. Rajeshkumar · 7 shared papers, 2012–2020 · strength 0.39
  2. Anirban Maitra · 7 shared papers, 2012–2020 · strength 0.39
  3. Manuel M. Hidalgo · 5 shared papers, 2012–2017 · strength 0.22
  4. Roeland F. de Wilde · 4 shared papers, 2012–2020 · strength 0.20
  5. Zeshaan A. Rasheed · 3 shared papers, 2012–2020 · strength 0.15
  6. Daniel D. Von Hoff · 2 shared papers, 2016–2020 · strength 0.15
  7. Jurre J. Kamphorst · 2 shared papers, 2015–2017 · strength 0.11
  8. Joshua D. Rabinowitz · 2 shared papers, 2015–2017 · strength 0.11
  9. Chi Van Dang · 2 shared papers, 2015–2017 · strength 0.11
  10. Peter James O'Dwyer · 1 shared paper, 2020 · strength 0.09
  11. Robert A. Anders · 1 shared paper, 2020 · strength 0.09
  12. Bhavina D O Batukbhai · 1 shared paper, 2020 · strength 0.09
  13. Ana De Jesus‐Acosta · 1 shared paper, 2020 · strength 0.09
  14. Asma Begum · 1 shared paper, 2020 · strength 0.09
  15. Ramesh K. Ramanathan · 1 shared paper, 2020 · strength 0.09
  16. Lei Zheng · 1 shared paper, 2020 · strength 0.09
  17. Florencia M. McAllister · 1 shared paper, 2020 · strength 0.09
  18. Daniel A. Laheru · 1 shared paper, 2020 · strength 0.09
  19. Victoria H. Cruz · 1 shared paper, 2018 · strength 0.07
  20. Mary Topalovski · 1 shared paper, 2018 · strength 0.07
  21. Wenting Du · 1 shared paper, 2018 · strength 0.07
  22. Kathleen F. Ludwig · 1 shared paper, 2018 · strength 0.07
  23. Rolf A. Brekken · 1 shared paper, 2018 · strength 0.07
  24. Masamichi Mizuma · 2 shared papers, 2012–2014 · strength 0.06
  25. Anne Le · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.